RGNA - Regeneca™ International Inc.

RGNA - Regeneca™ International Inc.

About RGNA
Regeneca™ International, Inc. was formed to create premium products that help to improve health and fight the signs and symptoms of aging for a complete life of wellness and happiness.

We specialize in direct response marketing. We drive customer acquisition, alongside direct sales networking. With our direct response network, we've created a revolutionary approach to home business ownership. Through television, radio, online, and print advertising, we can help to brand and commercialize your business, while developing a customer base and sales organization stretching across the globe.

http://youtu.be/ejW6j-o7msA

RGNA Security Details
Regeneca™ International, Inc. is a publicly traded on the OTC Market under the symbol, “RGNA”, and within the OTC Pink Limited market tier.

Visit http://www.otcmarkets.com/stock/RGNA/quote for more information.

Market Value1 $652,409 a/o Nov 25, 2011
900 million o/s source: by the company jimmy@regeneca.com

shares from 10Q
As of June 30, 2010, (the last day of the fiscal quarter to which this report relates), there were 102,226,177 shares of the registrant’s $.0001 par value common stock issued and outstanding, and as of September 2, 2011 (the latest practical date) there were 952,844,037 shares outstanding.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8146357

Transfer Agent
Action Stock Transfer Corporation
2469 E. Fort Union Blvd., Suite 214
Salt Lake City, UT 84121
Telephone: (801) 274-1088
Fax: (801) 274-1099
Email: justblank2000@yahoo.com

Shareholders of Record: 778 a/o Apr 15, 2009
SIC - Industry Classification: SIC # 2992
Incorporated In: NV, USA
Year of Inc.: Regeneca, Inc. (the “Company” or “Regeneca”), formerly Ethos Environmental, Inc., was incorporated under the laws of the State of Nevada on January 19, 1926

Security Notes
Capital Change=shs decreased by 1 for 1200 split. Pay date=11/16/2006.

Company Notes
Formerly=Ethos Environmental, Inc. until 6-2011
Formerly=Victor Industries, Inc. until 11-06. State of Incorporation Idaho changed to Nevada concurrent with name change

Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com
(these are only sources and not always up to date)

RGNA Products & Services
As we age, our bodies become more susceptible to health issues, and for some people this can include cancer, cardiovascular disease, immune system decline, Alzheimer's disease, Parkinson's disease, diabetes, rheumatoid arthritis, cataracts and erectile dysfunction.

Studies have identified a diet rich in fruits and vegetables may help us to stay healthy due to high concentrations of antioxidants and other beneficial compounds collectively called "phytochemicals". Antioxidants are an important type of phytochemical, and the good news is that there are many more health benefits still being discovered about this class of compounds.

Regeneca™ products aid in your dietary intake. RegenErect™ to support your sexual experience. RegeneBlend™ to rejuvenate you with its multiple extracts from a wide variety of phytochemical-rich plants.

The statements herein have not been evaluated by the Food and Drug Administration. Regeneca products are not intended to diagnose, treat, cure or prevent any disease.

RegenErect™ is a new groundbreaking discovery, an impact all-natural male enhancement product!

Natural RegenErect™, the male herbal supplement that everyone is talking about as couples discover how well it works for them. RegenErect™ is a natural herbal supplement designed to enhance sexual experience and intimacy between couples.

What is RegenErect™?
RegenErect is a new groundbreaking discovery, an impact all-natural male enhancement product! RegenErect is a Herbal Supplement that enhances the sexual experience! *

What are the ingredients in RegenErect™?
RegenErect™ contains a Drug-free blend of natural, herbal ingredients that enhance and support sexual experience: L-Arginine Extract, Epimedium PE, Silkworm Extract, Maca Root Extract, Green Tea 98%, White Willow Bark Extract, Spanish Red Oak Leaf Extract, Spanish Red Saffron Extract. 900 mg per capsule.

How fast does RegenErect™ work?
The capsules should be taken at least one hour before sexual activity and on an empty stomach for optimum results.**

Does RegenErect™ work for everyone?
Although results may vary by individual, we believe RegenErect™ works for most adult males 18 years or above.

Is RegenErect™ safe?
RegenErect™ is an herbal supplement formulated from drug-free natural ingredients in a gelatin capsule. As with any ingested product, it is recommended that you consult with your physician or licensed qualified health care professional prior to taking RegenErect™ if you have a medical condition.

RegenErect™ is a natural male enhancement supplement formulated for men of 18 years and above. It is not for use by women or individuals under the age of 18 years. Must not be used if pregnant or nursing. If you have any medical conditions or allergies that require medical attention, you should always consult your physician before taking any dietary supplement.

RegenErect™ is tested against non-detectable levels of Sildenafil, Tadalafil or Vardenafil. Lab results are available online.

How should I take RegenErect™?
Take 1 capsule with an 8oz. glass of water at least 1 hour before sexual activity. Frequent intake of water is recommended for a healthy and active lifestyle.

How often can I take RegenErect™?
A RegenErect™ capsule can be taken anytime prior to sexual activity.

What happens if RegenErect™ doesn't work for me?
Although results may vary by individual, we believe RegenErect™ works for most adult males 18 years or above.
We want you to be satisfied with the results of your performance using RegenErect™.

If you are not totally satisfied with RegenErect™, call 949-281-2600 and please see our Return Policy.

* These statements have not been evaluated by the Food and Drug Administration This product is not intended to diagnose, treat, cure, or prevent any disease

**Individual results may vary

RegeneSlim™ incorporates patented ingredients to perform several varied, yet important tasks that synergistically gives you more energy, reduces appetite and inhibits fat production!

Rigorously Tested
RegeneSlim™ is made in the USA from premium quality ingredients. Designed with your safety in mind, batches of RegeneSlim are tested in a state of the art Analytical Laboratory. This facility adheres to the current FDA cGMP guidelines. Regeneca™ has set a new standard in transparency in the dietary supplement industry by posting test results for all batches of RegeneSlim™ prior to sale or distribution. *All batch testing can be reviewed on this site.

The Benefits of RegeneSlim™
> No lifestyle changes
> No strong cravings
> No pre-packaged foods
> No weekly meetings
> No embarrassing weigh-ins
> No food restrictions

ChromeMate® is a unique patented form of oxygen-coordinated niacin-bound chromium found to be 18-times more bio-active than other forms of niacin-bound chromium that have been tested. Clinical studies** have shown that ChromeMate® lowers serum cholesterol and improves HDL (good) cholesterol levels, lowers blood pressure, reduces body weight, increases lean body mass and promotes proper insulin function in the body. It suppresses your appetite and increases your metabolism. It also increases insulin to deliver energy to your muscles while simultaneously decreasing body fat and sparing lean muscle mass.

Super CitriMax® is a patented, natural fruit extract from the South Asian fruit Garcinia Cambogia, shown to reduce appetite and inhibit fat production and weight. Super CitriMax® supports a healthy weight gain without stimulating the central nervous system.*** Super CitriMax® calcium/potassium bound HCA is also more soluble and better absorbed than other HCA products. This formulation of Super CitriMax® is manufactured under strict laboratory-controlled procedures to ensure optimum potency, purity and efficacy. Super CitriMax® has been determined GRAS (Generally Recognized As Safe) by a group of independent leading toxicologists.

RGNA Recent News
Monday, November 21, 2011
Regeneca(TM), Inc. Announces First to Market Mobile Technology for Distributors
GlobeNewswire (Mon, Nov 21)

Quote:

---

RegenecaTM, Inc. (Pink Sheets:RGNA) today announced that Regeneca's mobile technology is the first to market of its kind in the industry. Regeneca launched its mobile technology which allows distributors to post infomercials to their websites and to transact through a mobile device with customers and purchasers in the field. This technology also includes a QR code which distributors can attach to their cards and products which will direct users to a distributor's replicated site on any mobile device.

---

Monday, November 14, 2011
Regeneca(TM), Inc. Announces Successful Launch of Its Direct Response Network Marketing Business
GlobeNewswire (Mon, Nov 14)

Monday, November 7, 2011
Regeneca(TM), Inc. Announces Launch of www.vegaslaunch.com Website and Distributor Event Promotions
GlobeNewswire (Mon, Nov 7)

Quote:

---

RegenecaTM, Inc. (PinkSheets:RGNA.PK - News) today announced that it has launched www.vegaslaunch.com in support of its launch event in Las Vegas on November 11-12, 2011 at the Monte Carlo Resort & Casino. Additionally available to distributors of Regeneca are Double Dollar Days for attendees of the event only. Details of the event and promotions are available at www.vegaslaunch.com.

---

Tuesday, October 18, 2011
REGENECA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and Exhibits
EDGAR Online (Tue, Oct 18)

Wednesday, October 5, 2011
Regeneca(TM), Inc. Announces Change in Sales Support Strategy and National Launch Meeting Location
GlobeNewswire (Wed, Oct 5)

Tuesday, September 27, 2011
Regeneca(TM), Inc. Starts Shipping of the New Improved Impact Formulation for RegenErect(TM)
GlobeNewswire (Tue, Sep 27)

Management Team

http://youtu.be/bzNSLn00LQQ

Matt Nicosia
Chief Executive Officer/President/Co-Founder
Mr. Nicosia is one of those rare businessmen who combine top management skills with true entrepreneurship to inspire, challenge and motivate business partners. Mr. Nicosia is Chairman of Vivakor Inc. (VIVK.OB), a biotechnology research company, and additionally was founder and CEO of Dermacia a Southern California-based skin care company, which produced consumer, prescription and OTC products distributed through plastic surgeons and dermatologists as well as through retail and other mass-marketing channels. He has also been a director and co-founder of Quantum Sphere, Inc., a producer of nanomaterials and related technologies (www.qsinano.com). Mr. Nicosia received his Bachelor of Arts degree from Brigham Young University and an MBA from Pepperdine University.

James C. Short
Vice President of Investor and Vendor Relations - Co-Founder
Mr. Short earned his undergraduate degree from the Ohio State University, Columbus, Ohio in spring 1996. Mr. Short has a strong background in building businesses. A former executive in the skin care field, he was most recently the Senior Vice President of Sales and Marketing for a Southern California-based skin care company, Medici Biotech. He oversaw the company's sales grow from $10,000.00 to $150,000 per month in less than 2 years. Mr. Short also had 10 years in the telecom industry with tremendous success. He received presidents club and many other awards monthly, quarterly, and annually.

Sheri Sharman
Vice President of Marketing
Ms. Sharman is widely known in the direct sales industry. She has incorporated her passion for helping people into her professional career. Sheri has been a top income earner in every company in which she has participated. She has broken numerous sales records for both personal and team production, and she earned millionaire dollar status early in her career. Throughout her twenty-three years of experience as a direct sales professional, Sheri has incorporated innovative and results-oriented marketing strategies. She is recognized in the industry as having creative, forward-thinking and proven concepts in marketing and promotions. Sheri's passion is empowering women in all walks of life, and she holds regular Women's Empowerment Seminars throughout the U.S.

Dan Kerker
Chief Financial Officer
Mr. Kerker is a professional with 15 years experience in finance and accounting. He is a proven leader that works well with cross-functional teams to deliver financially sound, thoughtful plans that are supported throughout an organization. Most recently, he was the Director of Finance at Anheuser-Busch Sales of Los Angeles, an Anheuser-Busch-owned distributor with over $200 million in annual sales. He earned a Bachelors of Science in Finance from California State University, Northridge and an MBA in Finance from UCLA's Anderson School of Management, where he was a Harold M. Williams Fellow for graduating at the top of his class and won the J. Fred Preston Award for Achievement in Finance.

Advisory Board
Francis W. Chen - Dr. Chen is a Co-founder and Chairman of Pacific Advantage International - a marketing and sales support organization that assists U.S. and European information technology companies to establish sales and distribution channels in Asia-Pacific. He is also vice chairman at W.I. Harper, a venture capital firm operating in the U.S., China and Taiwan. Dr. Chen also serves on the board of directors of Solar Power, Inc. (OTC:SOPW). He brings over 20 years of top-level management experience in the healthcare industry, having held positions at Becton-Dickinson, Baxter Healthcare and Hygeia Sciences/Tambrands, among others. Dr. Chen earned his Ph.D. in immunology from Harvard University and holds an M.S. and a B.S. in chemistry from Tufts University.

RGNA Contact Info
Regeneca™ International, Inc.
1 Technology, Suite C-515
Irvine, CA 92618

Website(s)
http://www.regeneca.com
http://www.vegaslaunch.com
http://myregeneca.com
http://www.regenerect.com
http://regeneslim.com
http://theregenecadaily.com

Phone: 949-887-6890
facebook: http://www.facebook.com/regenerectintl

twitter: http://twitter.com/#!/regenecainc

As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile, Always do your own Due Diligence

Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, RGNA website, www.businessweek.com
(these are only sources and not always up to date)

NVSR - NavStar Technologies, Inc. dd

NVSR - NavStar Technologies, Inc. dd

About NVSR NavStar Technologies, Inc. engages in the production and commercialization of products and services for tracking/monitoring and reporting on the location and condition of high value cargo, equipment, and other valuable and personal assets. It primarily offers commercial/business global positioning system (GPS) tracking and monitoring products and services. The company's products include vehicle/portable asset tracker used to track and monitor vehicles, cargo, and other assets like trailers and heavy equipment; electronic on-board recorder, which is mounted to the dashboard of the vehicles and connects with the engine to provide users display of the vehicles activity; and personal asset tracker, a self-contained unit, including a the GPS system, digital cellular functionality, antennas, and battery that can be worn/carried by an individual or placed on small high-value assets for monitoring the unit’s location while in transit even over large distances. It also offers software services, such as driving directions, weather reports, and services related to nearest vehicle to a location. The company primarily focuses on the trucking, delivery, and services industry. NavStar Technologies, Inc. is based in Anaheim, California.

NVSR Security Details Share Structure Market Value1 $2,486,252 a/o Nov 23, 2011 Shares Outstanding 24,862,520 a/o Sep 30, 2011 Float 194,400 a/o Sep 30, 2011 Authorized Shares 100,000,000 a/o Nov. 14, 2011 (per last quarter report) Par Value 0.001 Security Notes * Capital Change=shs decreased by 1 for 24 split Pay date=07/30/2007. * Capital Change=shs decreased by 1 for 10 split Pay date=08/19/2008. * Capital Change=shs decreased by 1 for 150 split Pay date=12/16/2009. * Capital Change=shs decreased by 1 for 100 split. Pay date=08/29/2011. Shareholders of Record 1,518 a/o Sep 30, 2011 Financial Reporting/Disclosure Reporting Status Alternative Reporting Standard Audited Financials Not Available Latest Report Nov 14, 2011 Quarterly Report CIK 0001315049 Fiscal Year End 12/31 OTC Market Tier OTC Pink Current SIC - Industry Classification 3699 - Electrical equipment and supplies, misc Business Status Development Stage Company a/o Incorporated In: NV, USA Year of Inc. 2003

Company Notes * Formerly=European Diversified Holding Company until 7-07 * Formerly=European Day Spa & Tanning Salon Holding Company, Inc. until 7-02 * Formerly=Scotties Fish & Chips, Inc. until 8-01 http://www.otcmarkets.com/stock/NVSR/company-info Transfer Agent Corporate Stock Transfer, Inc. 3200 Cherry Creek Drive South Suite 430 Denver, CO, 80209 303-282-4800 Attorney Letter with Respect to Current Information http://www.otcmarkets.com/financialReportViewer?symbol=NVSR&id=65743 Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com (these are only sources and not always up to date)

NVSR Products & Services

http://www.navstarinc.com/_FileLibrary/FileImage/NSTRAK_EOBRPresentation.pdf

Vehicle/Portable Asset Tracker (VAT) Vehicle/Portable Asset Tracker NavStar has been able to leverage improvements in GPS and wireless technology to create a new tracking device that is smaller and more compact than its Vehicle/Asset Tracker (VAT). This product will enable the Company to track and monitor vehicles, cargo and other high value assets like trailers, heavy equipment, and just about anything that a customer deems as valuable.Tracking of vehicles for small to large trucking fleets is the main focus of the Vehicle/Portable Asset Tracker. The NavStar EOBR Mounted to the dashboard of the vehicles and connects with the engine. Information gathered from the engine, along with the GPS monitoring the unit provides, will give users an accurate display of the vehicles activity, and will be compliant with FMCSA regulations pertaining to the accurate recording of the drivers Hours of Service (HOS). The unit will transmit required data to a secure server for the Trucking companies to monitor, and the software provided by NavStar will fulfill all HOS regulations. The indiviual unit will also be able to send, or print, driver log books required for FMCSA HOS inspections. Since the unit will have GPS capabilities, it will also be able to assist the company in managing the costs assoicated with the operations of their vehicles and fleets. The company will be able to monitor the drivers activities and manage changes that might result in better gas mileage and other cost saving factors. Other benefits include asset tracking, and vehicle recovery. The use of NavStar's EOBR units will greatly enhance the recovery of stolen vehicles and/or merchandise.

Personal Asset Tracker The Personal & Asset Tracker is fully self-contained unit, including a the GPS system, digital cellular functionality, antennas and battery. Smaller than a deck of cards and weighing only 5 ounces, the unit is portable and can be worn/carried by an individual or placed on small high-value assets for monitoring the unit’s location while in transit – even over large distances. Once the units are powered on, they will automatically begin reporting their position - or remain “silent” depending upon the chosen configuration. Monitoring of the units can take place immediately via a subscription Internet service. Software Services Our GPS Tracking application covers all continental USA, Canada and Puerto Rico. The maps we use provide maximum quality and ease of use. Some of the features we offer are:

* Driving Directions * Weather Reports * Nearest vehicle to a location GPS Tracking System Features We offer a GPS Tracking system that has been developed completely based on the experience and feedback of our business team but most importantly on the experience of our customers. Our GPS Tracking solution is in an ever-changing process, based on two main streams: * The changing needs of our customers * The new opportunities offered by technology advances Our GPS Tracking / Fleet Tracking System gives answers to these and many other questions: * Where your drivers are * Where and when they have gone * How long have they been there * How is the weather or the traffic on their zone * Directions to get to the next stop * Closest vehicle to a given location * What driver is speeding * When a vehicle enters or leaves a defined zone

Mobility With our GPS Tracking system you will be able to monitor the location and status of your vehicles whenever, wherever. GPS Location, Track speed, direction, address and more using a portable device with browsing capabilities.

Technology You will be using the best GPS GPRS devices in the market to get continuous reporting and great flexibility. Keep this powerful tool and get... * Locating Vehicles & Crews * Theft Monitoring & Alerts * Remote Door Lock Control * Excessive Speed Monitoring * Fuel, Engine, Door, Battery Temp. Monitoring * Remote Ignition Control * Unauthorized Vehicle Usage Alerts * Roadside Assistance Request * Verify accuracy of time sheets, mileage reports, call reports * Ensure accurate customer billing for time & material work * Reduces your vehicle insurance rates * Increased Safety

NVSR Customers Fix Group Fix Equipment S.A., Ecuador This is for Fleet Management System (FMS) box and Mobile Display Unit (MDT) to distribute to Public Transportation System In Ecuador. IntelliSOL Corporation This is to be used in Automatic Vehicle Location (AVL), Stolen Vehicle Recovery (SVR) and Fleet Management System (FMS). Diamente, Mexico Mexico just passed regulation to have tracking system in all of new commercial vehicle sold in Mexico City in 2008. Diamente is one of few “approved vendors” in Mexico for this task and they are currently engaged in contract discussion with major vehicle manufacturers for Mexico Market. Diamente purchased test units and validate functionalities of system and they will launch this product in 3rd qtr of 2008. Navmex, Mexico Navmex has been distributing our products for past 18 months and this is a sign of distributorship growth in Mexico. AVL, Canada Following the successful evaluation of our units, and many in depth discussions of this date, Radio Service LCT intent to purchase from NavStar during next 12 months, minimum 1,000 units to be completed of a combination of following products, namely: FMS-G (CDMA-GSM) – WOV (Without Voice) Unit FMS-G (CDMA-GSM) – WV (With Voice) Unit FMS-G (GSM) – Slim (Smaller, affordable) Unit in late 2nd Qtr or early 3rd Qtr. The products are to be deployed in vehicle and asset tracking, security related applications employing Automatic Vehicle Location (AVL), Stolen Vehicle Recovery (SVR) and Fleet Management Systems throughout Mexico and other Latin American countries and North America. Wise Track/Brazil Vivo Wise has already taken delivery of the first 1,200 units. This customer has successfully launched solution in Brazil and selling quite well. Brazil is an important market as it opens the doors for many other countries in South America. CANTV CANTV is the parent company of Movilnet (CDMA Carrier) in Venezuela. Secusat - Latin America NavStar has developed and is manufacturing a line of Location Based Service (LBS) products, primarily focusing on Fleet Management Systems (FMS), Stolen Vehicle Recovery (SVR), security and risk mitigation service solutions. Secusat provides a hosted, end-to-end private labeled wireless location fleet management, stolen vehicle recovery, security and risk mitigation service solutions for wireless operators, insurance firms and security companies across Latin America. GeoSoft – USA GeoSoft has been selling Fleet Management systems for several years. They have selected NavStar products as their choice.

NVSR Recent News NavStar Technologies Signs Agreement With Trinity Noble, LLC to Add Cell Phone Detection Feature to EOBR Hardware and Service Offering 11/22/2011 8:30AM - Market Wire NavStar Technologies, Inc. Announces $2.4 Million in Funding From Southern California Investor Group 11/03/2011 9:00AM - Market Wire NavStar Technologies, Inc. Restructures and Positions Company for Significant Growth in 2012 08/29/2011 9:30AM - Market Wire NavStar Technologies, Inc. Announces Upgrade From Limited to Current Information at OTC Markets 06/17/2011 9:03AM - Market Wire NavStar Technologies to Partner With Trinity-Noble to Provide Cell Phone Detection Usage With EOBR Hardware and Service 06/10/2011 9:00AM - Market Wire Read more: http://www.nasdaq.com/aspxcontent/newsHeadlines.aspx?symbol=NVSR&selected=NVSR&SourceCode=PMZ#ixzz1eibZWuIO

NVSR Management Team
Chairman & CEO N. Douglas Pritt has 30 years experience at senior level positions in the telecommunications industry. Mr. Pritt has served as President & CEO of OnFiber Communications, Senior VP of Business Development at Sprint PCS, and various senior level management positions at Lucent Technology.
Jason Shin serves as President and CTO. Mr. Shin has served as Argo Chief Executive Officer and President since January 2003. Jason managed some of Interstate Electronics’ most important military GPS programs prior to leaving the firm to establish Axiom Navigation where he raised over $18 Million in equity financing. Jason Shin, assumed the role of President & CEO of Axiom Navigation and has worked for Rockwell Industries in their GPS divisions. Patrick Bannister serves as CFO and possesses over twenty years of experience in the Technology and Financial Services spaces. Pat holds a CPA designation in California, as well as several securities industry licenses. In addition, he has experience with a Big 4 Public Accounting Firm, is experienced in the Finance, Accounting and Operations of businesses of varied sizes and industries.
Chief Scientist and Advisor Charles LaRue has worked for many aerospace companies developing airborne radar systems, avionics operating and maintenance software, graphics software, aircraft simulation, and IFF systems. These companies include Lockheed, ITT Gilfillan, Teledyne, and Litton. In the mid-80’s he first conceived the idea of a car navigation system that gave turn-by-turn directions to the driver and has continued to advance the state-of-the art in voice navigation systems.

NVSR Contact Info NavStar Technologies, Inc. 800 South Harbor Blvd. Suite 220 Anaheim, CA 92805 Website: http://www.navstarinc.com Phone: 714-502-6900 Email: info@navstarinc.com

As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile, Always do your own Due Diligence Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, NVSR website, www.businessweek.com (these are only sources and not always up to date)

Davi Luxury Brand Group - MDAV

Davi Luxury Brand Group - MDAV

ABOUT DAVI - MDAV

IN 1966, Robert Mondavi founded a winery with a mission to create a California wine that would stand up to the elite wines of the world. The result is a brand synonymous with quality and California wines the world over.

Forty years later, his grandson Carlo Cesare Mondavi has ventured out from his family’s sacred Napa Valley vineyards to create something alike in the skincare business—a luxury product that not only reflects the California lifestyle fostered by his family’s wine, but performs better than the already established skincare regimes available today.
He turned to what he knew best, as a third generation vintner, Carlo Mondavi has created a line of skincare with roots firmly planted in his family’s vineyards.
The result is Davi, a new line of luxury skincare encompassing the unique byproducts of the winemaking process coupled with the latest innovations in modern technology.
The company markets skincare products under the “DAVI Skin” and “DAVI” brand names. The products currently are provided as amenities at prestige hotels and as first class in-flight airline amenities.
The company’s goal is to also market its branded skincare products through upscale department stores, specialty retailers, prestige resorts, salons and spas, on cruise ships, and through airline duty-free shops.

The company’s skincare products contain minerals, vitamins and nutrients that are found in a by-product of the wine making process called the pomace.
Planting techniques at select vineyards produce deeper vines with a lower yield of grapes per vine. After processing, these grapes yield higher concentrations of minerals, vitamins, and nutrients than grapes from other vineyards. Additionally, the uniquely long maceration process to which these grapes are subjected, yield polyphenols in relatively high quantity.

Polyphenols are the free radical scavengers that, among other things, help to protect collagen and elastin fibers and prevent the destruction of hyaluronic acid in the skin.
Management believes that the use of this pomace will allow for the creation of skin crèmes that can help fight the natural aging process of the skin.

AT THE CORE of all our products is a proprietary microencapsulated anti-aging antioxidant complex called Meritage.

Created in close collaboration with laboratories in Lyon, France, Meritage is a unique blend of grape and fermented wine extracts, green tea, raspberry, black currant and bilberry extracts, rosemary and olive leaf extracts. Meritage is created through a unique double fermentation process and preserved in the formula until the moment it is applied to the skin.
Because it is microencapsulated, the select high-level antioxidants of Meritage are able to remain active on the skin hours longer than conventionally created products. Meritage's sustained time-release technology provides a slow infusion of antioxidant health benefits to the skin. A daily regimen of Davi skincare restores and rejuvenates, leaving your skin the picture of health—young, radiant and full of life.



http://www.youtube.com/watch?v=4DwC6PbG ... e=youtu.be


PRODUCTS and SERVICES



Womens Collection

Le Grand Cru for Women
Nourish Protect Restore



The centerpiece of the women's treatment line, Le Grand Cru is an ultra luxurious cream designed to provide a long-lasting slow-released infusion of antioxidants and moisture to the skin, leaving skin smoother, softer and more supple.
Le Grand Cru focuses on a woman's skin needs by providing intense hydration, transforming dry, dull skin into a younger, more radiant complexion. Formulated with moisturizing shea butter, rosemary, green tea, grape extracts and vitamin E to fight free radicals, and our exclusive Meritage anti-aging complex, all blended to create the ultimate anti-aging cream for women.

Application:

To activate the meritage creme and release its key ingredients, warm a small amount between your fingertips.
As you pat onto clean, dry skin, you will instantly feel the soothing effects of the blend. Smooth over your face, neck, even under the fragile eye area. Apply day and night – for a lifetime.

VINE FRESH SPF 30 LOTION

An everyday light moisturizer with UVA/UVB protection of SPF 30. Vine Fresh SPF 30 Lotion provides the skin with nourishment and protection from the sun, leaving a healthy, radiant glow.
Formulated with shea butter to moisturize, bioactive ingredients from the healing herb centella asiatica to bring youthfulness and radiance to the skin, vitamin E and white tea to fight free radicals, spring sea water from Ile Grande on Cote de Granit Rose in Northern Britain to nourish the skin, and our exclusive Meritage anti-aging complex



MOSCATO PURIFYING CLEANSER



A luxuriously gentle creamy cleanser and conditioner. Moscato Purifying Cleanser leaves skin smooth and silky.
Formulated with glycerin for effective cleansing, coconut derived emollient and grapeseed oil for smooth, lustrous skin, and our exclusive Meritage anti-aging complex.


HARVEST MIST TONER


A super hydrating spray mist for toning, hydrating, and refreshing dull looking skin. Harvest Mist Toner improves overall balance as it soothes.
Formulated with witch hazel and extract from the mushroom polyporus officinalis to improve skin's tone and firmness, grapeseed oil for enhancing the skin's radiance and glow, and our exclusive Meritage anti-aging complex


LE GRAND CRU


The centerpiece of the women's treatment line, Le Grand Cru is an ultra luxurious cream designed to provide a long-lasting slow-released infusion of antioxidants and moisture to the skin, leaving skin smoother, softer and more supple.
Le Grand Cru focuses on a woman's skin needs by providing intense hydration, transforming dry, dull skin into a younger, more radiant complexion. Formulated with moisturizing shea butter, rosemary, green tea, grape extracts and vitamin E to fight free radicals, and our exclusive Meritage anti-aging complex, all blended to create the ultimate anti-aging cream for women.

brochure for women: http://www.daviskin.com/womens-brochure/





LE GRAND CRU for Men





The linchpin of the men's line, Le Grand Cru is an ultra-luxurious cream designed to provide an infusion of antioxidants and moisture to the skin.

Le Grand Cru addresses concerns particular to a man's skin, including irritation and dryness. Formulated with moisturizing shea butter, free-radical-fighting antioxidants such as rosemary, green tea, grape extracts and vitamin E, as well as ginseng, witch hazel and allantoin, a botanical extract of the comfrey plant, for toning and astringent benefits, and our exclusive Meritage anti-aging complex.


CRUSHED GRAPE SEED EXFOLIATING CLEANSER


An innovative cleansing formula to gently remove and exfoliate excess oil and dead skin cells in preparation for a clean shave.
Crushed Grape Seed Exfoliating Cleanser is formulated with moisturizing Bilberry, Soybean, Raspberry, and Olive Oil, exfoliating Grapefruit Powder and free radical fighting antioxidants Vitamin A, Vitamin E and Vitamin C, along with our exclusive Meritage anti-aging comple


RESERVE SHAVE CREAM


A moisturizing daily shaving cream perfect for any skin type.
Reserve Shave Cream is designed to provide the closest shave, leaving the skin smooth and sleek. Formulated with free radical fighting antioxidants such as grape leaf extract, green tea, vitamin E and vitamin C, along with our exclusive Meritage anti-aging complex.





VINE FRESH SPF 15 LOTION


A light, non-greasy everyday moisturizer with UVA/UVB protection of SPF 15.

Vine Fresh SPF 15 Lotion provides the skin with nourishment and protection from the sun, leaving a healthy, radiant glow. Formulated with shea butter to moisturize, bioactive ingredients from the healing herb centella asiatica to bring youthfulness and radiance to the skin, vitamin E and white tea to fight free radicals, spring sea water from Ile Grande on Cote de Granit Rose in Northern Britain to nourish the skin, and our exclusive Meritage anti-aging complex.


COASTAL VINE AFTERSHAVE


A refreshing after shave serum to calm, cool and close pores and to aid in the prevention of irritation.

Coastal Vine After Shave's soothing properties reduce redness and irritation caused by the shaving process. Formulated with free radical fighting antioxidants such as fermented wine extract, green tea, vitamin E and vitamin C along with ginseng and witch hazel for toning, and our exclusive Meritage anti-aging complex.

brochure for men: http://www.daviskin.com/mens-brochure/




MDAV Management Team

Parrish Medley
Chief Executive Officer, Secretary, Director and President

Officer since February 2010
48 Years Old
Parrish Medley currently is the President and Chief Financial Officer of Regal Group, Inc. Group, Insince February 2010. Mr. Medley also has been a member of the Board of Directors of Regal Group, Inc. since February 2010 and its President since August 2010. Regal c. is a public company engaged in the business of developing and integrating off-the-shelf and proprietary RFID solutions.

Mr. Medley co-founded Davi Skin, Inc. in 2003 and subsequently served as its President until December 2006. Between 2006 and 2010, Mr. Medley was involved in real estate and venture capital investments for his own account. Mr. Medley was a venture capitalist and a private money manager from 1997 to 2004. His previous experience includes roles as manager and financial consultant for numerous registered broker dealers, including Bear Stearns & Co. From 1999 to 2001 he was a partner at century financial partners a venture capital firm.

Mr. Medley also founded Palm Beach Tan one of the nation?s largest indoor chains and franchise operations as well as Mystic Tan one of the largest spray on tanning systems in the world doing combined revenues approaching 100 million dollars.

Effective December 30, 2010, Upon Mr. Beddome?s resignation, Parrish Medley became Chief Executive Officer, interim Chief Financial Officer, and Secretary of the Company. Prior to Mr. Rice?s appointment as the Company?s Chief Financial Officer, Parrish Medley, the Company?s President, Chief Executive Officer and Secretary, acted as the Company?s interim Chief Financial Officer.
http://people.forbes.com/profile/parrish-medley/92163

J. Bernard Rice
Director and Chief Financial Officer

Beverly Hills , CA
Officer since February 2011
Director , Omni Ventures, Inc.
56 Years Old


Effective April 27, 2011, Davi Luxury Brand Group, Inc. appointed J. Bernard Rice to serve on the Board of Directors of the Company. J. Bernard (Bernie) Rice ? Mr. Rice began his career with IBM in sales as a medical specialist in Atlanta in 1977.

In 1983, Mr. Rice entered IBM?s finance fraternity and was an active pioneer of IBM?s business approach to software as a strategic imperative. His work in business case structure and portfolio analysis led him to a role as IBM?s finance director for application software in 1985. Reporting directly to the General Manager, Mr. Rice was responsible for the financial management of over 6,000 IBM software developers, responsible for over $500 million in annual company revenues.

Mr. Rice joined IBM?s corporate financial team in 1987 and led the company?s restructuring effort. Mr. Rice was promoted to Executive Assistant to IBM Chief Financial officer in 1989. In this role he led several cross?industry executive groups who initiated IBM?s first Enterprise agreements with top customers.

Mr. Rice was named Director of Finance, Planning and Administration for IBM?s Southern Area in 1990. There he had responsibility for the staff functions comprising over $3 billion in IBM revenues. Mr. Rice was instrumental in positioning IBM?s southeast region as the leader in billable services. In 1993, Mr. Rice became Chief Financial Officer and General Partner for IBM Venture Capital Group. In this role Mr. Rice was highly involved with IBM?s ventures with Apple Computer, Blockbuster Entertainment Joint Ventures, and investments in the Media Industry and video on demand pilots with Bell Atlantic and Cox Cable.

Mr. Rice also was responsible for managing IBM?s first steps in the consumer software arena. Mr. Rice became VP of Business Development for IBM?s Consumer Division in 1998. Mr. Rice also served as CEO of Edmark, Inc., IBM?s subsidiary which developed innovative educational software for kids.

In late 2000, he orchestrated the successful spin?off of IBM's education content assets into Riverdeep, Inc., after which he became the Executive VP responsible for all sales and business development. Mr. Rice was a vital part of Riverdeep's explosive growth, helping it to become the fastest growing educational software company in the United States. Today Riverdeep has educational products in 45,000 schools in over 20 countries.
http://people.forbes.com/profile/j-bernard-rice/152618

Carlo Mondavi
Chairman of the Board

Beverly Hills , CA
30 Years Old
Carlo Cesare Mondavi, Chairman of the Board is a member of the Mondavi winegrowing family from Napa Valley, California. Mr. Mondavi worked at the Robert Mondavi Winery from 1987 until 2003.

Since 2008 he has worked at Continuum Estate with the sales team where he currently serves as the Western Regional Sales Manager. Continuum Estate is an artesian winery that was founded in 2005 by his grandfather Robert Mondavi and father Tim Mondavi. Mr. Mondavi studied International Business at the University of Aix en Provence, France and Language Studies at the University of Milan, Italy. He founded Davi Skin, Inc. in 2003 with the vision of improving skin health with the luxurious antioxidants found in wine and grapes. He resigned as an officer and director from Davi Skin, Inc. in July 2008.
http://people.forbes.com/profile/carlo-mondavi/25317

Carlo Mondavi is the grandson of American Icon Robert Mondavi (Founder of Robert Mondavi Winery, and co-founder of Continuum Winery Estate) where through his grandfather and family instilled in him was a legacy of family values and business ethics that he honors vigorously.

Mr. Mondavi began working at the Robert Mondavi Winery in 1987. He now sits on the family council of Continuum Estate and actively participates in the wine business and Continuums special events for sales and marketing.




RECENT PRESS RELEASES


Tue, Jul 05, 2011
DAVI LUXURY BRAND GROUP Appoints Shaun Wylie as Chief Operating Officer - Business Wire

Mon, May 09, 2011
Davi Luxury Brand Group Inc Announces Today It Has Engaged Hansam Moolsan Co., LTD for Its Duty Free Business in the Airline Industry. - Business Wire

Mon, May 02, 2011
DAVI LUXURY BRAND GROUP Announces a Multi-Year Agreement with KOREAN AIR to Be the Exclusive First Class and Business Class In-Flight Amenity Provider for All KOREAN AIR Flights Worldwide - Business Wire

Wed, Apr 27, 2011
DAVI LUXURY BRAND GROUP Announces J. Bernard Rice to Join Board of Directors -Business Wire

Mon, Mar 14, 2011
DAVI LUXURY BRAND GROUP, INC. Announces Reality TV Star Taylor Armstrong as Spokesperson for DAVI Skin Care - Business Wire

Wed, Feb 23, 2011
DAVI LUXURY BRAND GROUP is Pleased and Honored to Be the In-Room Amenity Provider for All Peninsula Hotels Worldwide - Business Wire

Tue, Feb 22, 2011
DAVI LUXURY BRAND GROUP Is Pleased and Honored to Be the in Room Amenity Provider for All Peninsula Hotels Worldwide - Business Wire

Fri, Feb 18, 2011
Company Profile for DAVI LUXURY BRAND GROUP, INC. - Business Wire

Wed, Feb 16, 2011
DAVI LUXURY BRAND GROUP Appoints J. Bernard Rice as Chief Financial Officer -Business Wire

Tue, Jan 25, 2011
Davi Luxury Brand Group, Inc. Announces Name Change and New Ticker Symbol - PR Newswire



CONTACT MDAV

MDAV Contact Info

Davi Luxury Brand Group
9426 Dayton Way
Beverly Hills, CA 90210
Office: 310.288.8393
Fax: 310.288.0125
info@daviskin.com
website: http://www.daviskin.com
facebook: http://www.facebook.com/mdav.davilux


Sources: otcmarket.com, http://www.bloomberg.com, http://www.finance.yahoo.com, MDAV website, http://www.businessweek.com
(these are only sources and not always up to date)

CURX ~Curaxis Pharmaceutical Corporation~ dd

CURX ~Curaxis Pharmaceutical Corporation~ dd
CURX.OB (Frankfurt: 8CX)

The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be held on November 8th 2011. Please click here to download the proxy materials and to vote:

https://www.iproxydirect.com/index.php/CURX

About CURX.OB (Frankfurt: 8CX)

Curaxis Pharmaceutical Corporation is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. 

Click Here For Video: http://blog.curaxispharma.com/media/

CURX Security Details
Curaxis Pharmaceutical Corporation is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, “CURX”, and within the OTCQB market tier. As such, Business, operational and financial information on CURX is fully transparent and available to public view.

Visit http://www.otcmarkets.com/stock/CURX/quote for more information.

Market Value1 $5,357,650 a/o Nov 03, 2011
Shares Outstanding 76,537,861 a/o Aug 11, 2011
Float 16,238,300 a/o Sep 15, 2010
Authorized Shares 480,000,000 a/o Aug. 12 2011
Par Value 0.0001
(per otcmarkets)

Per FORM 10Q link listed below
As of August 11 , 2011, there were 76,537,861 shares outstanding of the registrant’s common stock.
Common stock, $0.0001 par value; 480,000 authorized; 72,216 and 76,474 shares issued and outstanding at December 31, 2010 and June 30, 2011, respectively.

Transfer Agent
Direct Transfer, LLC.
500 Perimeter Park Drive Suite D
Suite D
Morrisville, NC, 27560
919-481-4000
www.issuerdirect.com
ta@issuerdirect.com

10Q reported Aug 12, 2011 period ending Jun 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721

Shareholders of Record: 41 a/o Apr 15, 2010
SIC - Industry Classification: 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc.: 2008 and On July 30, 2010, the Company entered into an agreement and plan of merger with Curaxis Pharmaceutical Corporation, a Nevada corporation formed solely for the purpose of a name change. Pursuant to the Short-Form Merger, the Company changed its name to Curaxis Pharmaceutical Corporation (“Curaxis” or the “Company”)

In February 2011, the Company was granted approval and listed its stock to trade on the Frankfurt stock exchange (“FSE”) under the symbol 8CX to expand its global capital markets access.

Security Notes
Capital Change=shs increased by 91 for 1 split. Ex-date=01/12/2010. Rec date=12/09/2009. Pay date=01/11/2010
Company Notes
Formerly=Auto Search Cars, Inc. until 9-2010

Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com

CURX Products & Services
CURX Pipeline

Our therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis. This platform is built on the premise that hormones associated with this axis are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer’s disease and various cancers. We believe our discovery of a duplicate HPG axis at the cellular level in brain tissue from Alzheimer’s patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer’s disease as well as many cancers. 

 

CURX Alzheimer’s Disease Program
Leuprolide acetate, a peptide hormone, has been widely used over the past twenty years for the treatment of a number of hormone-related disorders, most notably prostate cancer and endometriosis and precocious puberty, and has a well-established safety profile. Voyager has conducted extensive preclinical and clinical studies exploring the use of leuprolide acetate for the treatment of Alzheimer’s disease in mild-to-moderate patients. The results to date are very encouraging and point especially to a potentially significant new treatment for women with Alzheimer’s disease.

Women represent approximately two-thirds of Alzheimer’s patients. Men present greater challenges in the use of leuprolide to treat Alzheimer’s disease because leuprolide suppresses their production of testosterone, which could necessitate patient self-administration of supplemental testosterone and which can lead to wide swings in testosterone blood serum levels. Therefore, in the near-term, we plan to concentrate our development efforts on the use of leuprolide acetate to treat women, although we will continue our efforts to better understand mechanisms that might lead to optimum outcomes in men.

This Video is Patrick Smith Of Curaxis Pharmaceutical Corporation - Alzheimer Disease
Lists him as CEO but he is no longer the CEO, but it explains Alzheimer's and the company Brilliantly! 

http://www.youtube.com/watch?v=XdMmQ6ppDnU

CURX Oncology Program
We have conducted an extensive preclinical research program in the use of leuprolide acetate to treat a number of cancers, including hor mone refractory prostate cancer, brain cancers, kidney cancer, pancreatic cancer and non-small-cell lung cancer.

Our work in oncology is based on new insights into the growth of cancer cells that have been discovered by our scientists. In particular, our scientific findings relating to autocrine-paracrine signaling and the replication of the hypothalamic-pituitary-gonadal axis (the HPG axis) inside of cancer cells point to a previously unknown mechanism that drives the growth of cancer cells and an entirely new method of attacking those cancer cells; i.e., using high doses of leuprolide acetate to eliminate the gonadotropins that may be driving the growth of those cells.

Our preclinical testing of this new treatment approach has produced extremely encouraging results. In both in vitro and in vivo experiments, we have demonstrated a potentially important new therapy for the treatment of a number of cancers.

We plan to use the same compound for our various cancer Phase II clinical trials as we are using for clinical trials of VP4896. Since we have completed Phase I safety trials of VP4896, we believe that we will be able to commence our clinical programs for various cancers with Phase II clinical trials instead of Phase I safety trials. However, the FDA will have to agree to the commencement of these clinical programs with Phase II clinical trials when we submit our Investigational New Drug Applications, or INDs, to the FDA.

 

History
Curaxis’ history dates to an insight from the mid-1990’s concerning how changes in various hormone levels impact our health as we age. Most everyone knows that, as we age, our hormone levels change. In particular, it is well known that as we age, levels of estrogen decline precipitously in women, leading to menopause, and levels of testosterone gradually decline in men, leading to andropause. However, while a great deal of research has previously been devoted to the effects of declining estrogen and testosterone on our health, including our mental abilities, Curaxis has taken this research in a broader direction.

Specifically, Curaxis was founded in 2001 (as Voyager Pharmaceutical Corp.) to take a step back from a singular focus on estrogen and testosterone to examine the entire HPG axis, which regulates production of estrogen and testosterone throughout our lives. Curaxis’ initial hypothesis was that changes in the levels of hormones in this axis other than estrogen and testosterone play a key role in various diseases of aging. During 2001 and the years that immediately followed, Curaxis devoted substantial research to testing this hypothesis. Also during 2001, Curaxis was awarded a broad patent covering its unique approach to the treatment of Alzheimer’s.

As a result of Curaxis’ research, it became increasingly clear that one hormone of the HPG axis, called luteinizing hormone or LH, may play a central role in the pathologies that lead to Alzheimer’s as well as other diseases of aging, including many cancers. Levels of LH increase dramatically as women enter menopause and increase substantially in men as they age and testosterone production declines. In numerous preclinical studies, Curaxis’ research showed that these increased levels of LH were likely a key contributor to developing Alzheimer’s.

 

Developing A Focus
Having determined that high levels of LH represented a potential cause of Alzheimer’s, Curaxis then focused on using leuprolide acetate, which eliminates or dramatically reduces LH levels, as a treatment for Alzheimer’s. Curaxis’ focus on LH followed two parallel paths.

First, in 2002, Curaxis entered into an agreement with Durect Corporation to develop a proprietary implant that would release leuprolide acetate at targeted levels over a two month dosing period. Work on development of this implant commenced in 2002 and culminated in 2005 with a successful Phase 1 trial of the safety and tolerability of the implant.

Second, because leuprolide acetate had been used for many years to treat other diseases, including prostate cancer, in early 2003 Curaxis commenced a Phase 2 clinical trial to treat mild-to-moderate Alzheimer’s in women, using a commercially available dose of leuprolide. In addition, in late 2003 Curaxis commenced a Phase 2 clinical trial to treat mild-to-moderate Alzheimer’s in men, again using a commercially available dose of leuprolide.

This parallel path enabled Curaxis to significantly shorten development for its Alzheimer’s candidate. As a result, by mid-2005, Curaxis had successfully completed dosing in the Phase 1 trial of its proprietary implant developed with Durect, which Curaxis calls Memryte, and had also completed its Phase 2 trial of leuprolide in women. The results of both of these trials were encouraging and Curaxis began making plans for Phase 3 trials of Memryte. Based on FDA filings and a meeting with the FDA in August 2005, Curaxis launched its Phase 3 trials of Memryte in September 2005.

Also in September 2005, Curaxis (then Voyager Pharmaceutical) filed for its initial public offering, in order to raise sufficient funds for its Phase 3 trials. Based on the strength of its preclinical and clinical data and its management, it was anticipated that a successful IPO would follow later in 2005. Unfortunately, a leading contributor to the research and a significant shareholder of the company took medical leave at the height of these efforts. Complications associated with his illness and absence forced the company to withdraw from the IPO process.  

 

Initial Results
The results of the Phase 2 clinical trial in men were obtained in mid-2005. However, although there were positive signals in those results, the results were confounded by the need to provide supplemental testosterone to men on active treatment in the trial.

During 2006, Curaxis renewed its efforts to obtain private capital to complete its Phase 3 trials. Although it enjoyed some success, it was unable to obtain the full amount needed and was forced to terminate the Phase 3 trials in late 2006. During the remainder of 2006 and 2007, Curaxis worked to obtain the maximum amount of data from these terminated trials. Although the data was incomplete due to the early termination of the trials, the date obtained provided further support for the use of leuprolide to treat mild-to-moderate Alzheimer’s, particularly in women.

During 2008 and 2009, Curaxis has regrouped in its efforts to move forward with Memryte. Although Curaxis was unable to make progress in the clinical development of Memryte during this period, the field of Alzheimer’s research was not static during this period. A number of Phase 3 Alzheimer’s trials, which focused on a target called beta amyloid to treat Alzheimer’s, failed to meet their endpoints during 2007-2009. Curaxis has long believed that a focus solely on beta amyloid as a target to treat Alzheimer’s is incorrect and the failures of these trials support that view. Most importantly, Curaxis believes that the failure of these trials will broaden acceptance of other approaches to treating Alzheimer’s, including Curaxis’ approach.

In 2009, Curaxis entered into a series of agreements with Southridge Business Solutions Group (“Southridge”) in order to restructure its balance sheet and establish a trading market for its common stock. Under the terms of those agreements, Southridge assisted Curaxis in negotiating settlements with its creditors to eliminate or substantially reduce and defer its trade debt. To date, Curaxis has realized reductions in excess of $6 million in liabilities as the result of the combined efforts. In addition, Southridge assisted Curaxis in securing a $25 million equity facility under which the Company can periodically, over a period of three years, sell up to $25 million of its common stock to an affiliate of Southridge. On December 8, 2010, the Company filed a Registration Statement on Form S-1 to register 13,000,000 shares of comm on stock to be reserved for issuance under the Equity Line Facility.The proceeds of the equity facility will be used, in part, to fund the next steps in the Company’s clinical development plan.

In July, 2010, Curaixs completed a reverse merger into a public shell Corporation. As a result, the Company's common stock is now traded on the OTC Quote Board under the symbol "CURX." In addition, Curaxis began trading on the Frankfurt Stock Exchange under the ticker “8CX” on February 7, 2011.

On June 27, 2011, the Company announced changes to its Board of Directors (the “Board”) and its executive management team to better position the Company for its next phase of growth and development. The new Board has a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in all of the necessary industry arenas to execute the Company’s business plan on an accelerated basis.

 

Going Forward
The Board is in the process of completing a comprehensive analysis of the financial position of the Company and is evaluating potential funding alternatives. In addition, the Board has been focused on several remaining transition items including, but not limited to, the efficient processing of capital transactions for pre-merger shareholders, the scientific evaluation of the Company’s inventory of pre-clinical and clinical data and related intellectual property and, the development of strategic alternatives.

DOWNLOAD: Alzheimers Research Report (PDF)
http://www.curaxispharma.com/images/pdf/alzheimers_research_report.pdf

BLOGS http://blog.curaxispharma.com/

Milestones: http://www.curaxispharma.com/index.php?option=com_content&view=article&id=52&Itemid=69
Links: http://www.curaxispharma.com/index.php?option=com_content&view=article&id=54&Itemid=71
Reference: http://www.curaxispharma.com/index.php?option=com_content&view=article&id=55&Itemid=72

CURX Partners
Curaxis has engaged a very impressive infrastructure of scientific/technical, medical and legal advisers as strategic partners. This allows the Company to leverage talented individuals who provide key knowledge, expertise and support. A selection of these partnerships is represented by:

• Our collaboration in discovery research with leading Alzheimer's research teams led by George Perry, PhD, Mark A. Smith, PhD (http://www.cwru.edu/med/pathology);
• Leading patent and FDA legal support from Covington & Burling (http://www.cov.com);
• Clinical and FDA regulatory support from Bert Spilker & Associates (http://www.bertspilker.com);
• Drug development and delivery support from DURECT Corporation (http://www.durect.com);
• Website and marketing communications support by Sage Communications, LLC. (http://www.aboutsage.com)

Case Western Reserve University - Department of Pathology
World-class research is conducted in the Department of Pathology with major emphasis on the following areas and more: cancer biology, infection and immunity, neurobiology/neuropathology, tissue injury and healing, and biomaterials biocompatibility. These emphasis areas are reflected in the three tracks of the Pathology Graduate Program: the Cancer Biology Training Program (CBTP), the Immunology Training Program (ITP) and the Molecular and Cellular Basis of Disease Training Program (MCBDTP). The Pathology Graduate Program provides extensive opportunities for PhD or MD-PhD training in these areas. A separate program leads to the MS degree.

Covington & Burling LLP
Covington & Burling LLP represents clients in cutting-edge technology, litigation, white collar defense, transactional, governmental affairs, international, life sciences and other matters. In responding to the needs and challenges of our clients, our lawyers draw upon the firm’s expertise and experience in a broad array of industries to provide solutions to difficult, complex, and novel problems and issues, whether in litigation, transactions, or regulatory proceedings.

Bert Spilker & Associates
The mission of Bert Spilker & Associates (BS&A) is to provide clients with the highest quality, most cost-effective, and timely pharmaceutical consulting services available. To achieve this goal, Bert has assembled a group of over 150 independent associates who are available to assist him in most aspects of drug discovery, drug development and strategy setting. BS&A strives to build long-term relationships with clients based on knowledge of his clients culture, research, products and services.

Sage Communications Advertising and Public Relations
Sage Communications is a full-service, integrated marketing firm that provides advertising, public relations, and strategic marketing services to clients from across the street to across the globe, from emerging start-ups, to major Fortune 500 companies. Throughout our history, our mission has remained the same: Align marketing strategy to directly impact our clients' bottom line. We are located in Tysons Corner, VA

CURX Recent News

RED HOTT

The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be held on November 8th 2011.

Quote:

---

Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Curaxis' initial focu s is Alzheimer's Disease (or AD). The lead product is a patented treatment, Memryte, that has shown the potential for treating and halting the progression of this devastating disease.
The Problem
Washington DC, May 19, 2010, A new report from the Alzheimer’s Association, “Changing the Trajectory of Alzheimer’s Disease: A National Imperative” shows that in the absence of disease-modifying treatments, the cumulative cost of care for people with Alzheimer’s from 2010 to 2050 will exceed $20 trillion in today’s dollars.
The new report is not all bad news, however, as it shows that Medicare and Medicaid can achieve dramatic savings - and lives could be significantly improved - with even incremental treatment improvements.
Harry John’s, President & CEO of the Alzheimer’s Association said, “ Today, there are NO treatments that can prevent, delay, slow or stop the progression of Alzheimer’s disease. While the ultimate goal is a treatment that can completely prevent or cure Alzheimer’s, we can see that even modest improvements can have a huge impact.”
Market Need - Curaxis Solution
Currently marketed Alzheimer's drugs target the symptoms of Alzheimer’s disease by enhancing some patients’ cognitive function and general behavior, but generally are not thought to slow progression of the disease.
Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors - current theory) experience a modest improvement in cognitive function. According to the Alzheimer’s Association, for those patients who show improvement, the benefit typically lasts for only six months to one year.
Based on preclinical and clinical results achieved to date, Curaxis believes that Memryte may substantially slow the progression of Alzheimer's disease and represent a significant clinical improvement over current drugs.

---

Aug 17, 2011 Curaxis Pharmaceutical Corporation Management Working Through Transition Phase and Evaluating Alternatives 
Jun 27, 2011 Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials 
May 10, 2011 Curaxis Pharmaceutical Corporation Chief Executive Officer Comments on Recent NIH Research 
May 5, 2011 Curaxis' Memryte Named One of the Top 100 Drugs in Development Today by R&D Directions 
Mar 24, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Prana Research 
Mar 10, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent New York Times Article "Drug Firms Face Billions in Losses in '11 as Patents End" 
Feb 14, 2011 Curaxis Pharmaceutical Corp. to Meet With Ticino Business Development Office in Lugano, Switzerland 
Feb 9, 2011 Curaxis Pharmaceutical Corp. Announces New Listing on the Frankfurt Stock Exchange 
Feb 7, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Alzheimer's Association Report 
Feb 3, 2011 Curaxis Pharmaceutical Management on Roadshow in Europe to Access Capital & Pursue Strategic Partners 

CURX Core Management Team

Timothy R. Wright - Chairman and Interim Chief Executive Officer
A seasoned executive with over 25 years of life sciences experience, Timothy Wright has comprehensive operating and strategic management experience, which encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical services. Prior to joining Curaxis as Chairman of the Board and interim Chief Executive Officer, Mr. Wright was a Senior Vice President and President of the pharmaceuticals division at Covidien (Mallinckrodt). He previously served as President of Global Operations at Elan BioPharmaceuticals and spent 17 years at DuPont Merck Pharmaceuticals, where he was classically trained in the pharmaceutical industry. He brings significant global operating and product launch experience and has served on the boards of four public and four private global life sciences companies.

Judith S. T. Geaslen - VP Finance

Judith S. T. Geaslen has been the Company’s Vice President of Finance and Chief Accounting Officer since August 2009 after serving as Corporate Controller and Accountant since July 2004. From March 1999 to April, 2000, Ms. Geaslen served as Vice President and Corporate Controller at Wilmington Trust Corporation, a financial holding company engaged in providing a range of banking and other financial services through its banking and other subsidiaries, and from 1994 to 1999, served as Vice President and Manager of the Asset Review Division. From September 1984 to September 1994, Ms. Geaslen was employed by Ernst & Young, a registered public accounting firm, mostly recently serving as Audit Senior Manager. Ms. Geaslen is a graduate of Saint Mary’s College, Notre Dame, Indiana.

CURX Contact Info
Curaxis Pharmaceutical Corp
1004 Chagford Way
Raleigh, NC 27614

Website: http://www.curaxispharma.com
Phone: 888-919-2873
Email: jgeaslen@curaxispharma.com
twitter: http://twitter.com/#!/curaxispharma
facebook: http://www.facebook.com/pages/Curaxis-Pharmaceutical-Corporation/159104304105704

As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile, Always do your own Due Diligence

Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CURX website, www.businessweek.com
(these are only sources and not always up to date)

---